Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ironwood PharmaceuticalsFRA:I76 -0.54%65 Current Ratio is 6.06 as of Jun. 2026, which is 35% above its 10-year median of 4.48. GuruFocus rates FRA:I76 with a GF Score™ of 65/100 and a GF Value™ of €3.81 (Fairly Valued). The stock has 6 warning signs investors should review. Among 995 Drug Manufacturers companies, Ironwood Pharmaceuticals ranks better than 89.25% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ironwood Pharmaceuticals's current ratio for the quarter that ended in Jun. 2026 was 6.06.
Ironwood Pharmaceuticals has a current ratio of 6.06. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Ironwood Pharmaceuticals's Current Ratio or its related term are showing as below:
FRA:I76'
s Current Ratio Range Over the Past 10 Years
Min: 0.82 Med: 4.48 Max: 36.34
Current: 6.06
During the past 13 years, Ironwood Pharmaceuticals's highest Current Ratio was 36.34. The lowest was 0.82. And the median was 4.48.
FRA:I76's Current Ratio is ranked better than 89.25% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs FRA:I76: 6.06
Ironwood Pharmaceuticals (FRA:I76) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ironwood Pharmaceuticals Current Ratio Related Terms
Ironwood Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:I76 vs TLRY, AQST, ELTP: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals (FRA:I76) has a Current Ratio of 6.06 as of Jun. 2026. This is 35% above median its historical median of 4.48. Over the past decade, Ironwood Pharmaceuticals' Current Ratio has ranged from 0.82 to 36.34. According to the industry distribution chart, Ironwood Pharmaceuticals ranks #107 out of 995 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is Ironwood Pharmaceuticals' Current Ratio too high?
Ironwood Pharmaceuticals' current Current Ratio of 6.06 is 35% above median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 36.34. The Drug Manufacturers industry median Current Ratio is 1.97. Ironwood Pharmaceuticals' value of 6.06 is 207.6% above this industry median. Based on the distribution chart, Ironwood Pharmaceuticals ranks #107 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Current Ratio compare to TLRY and AQST?
According to the Drug Manufacturers industry distribution chart, Ironwood Pharmaceuticals ranks #107 out of 995 companies for Current Ratio. This places Ironwood Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.97. Ironwood Pharmaceuticals' value of 6.06 is 207.6% above this benchmark. Historically, Ironwood Pharmaceuticals' own Current Ratio has ranged from 0.82 to 36.34 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 1.97, Ironwood Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.97, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ironwood Pharmaceuticals's current Current Ratio of 6.06 is 207.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ironwood Pharmaceuticals's current Current Ratio is 6.06, which is 35% above median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (FRA:I76) is currently considered Fairly Valued. The stock's GF Value™ is €3.81, compared to a current price of €3.66 — trading 3.9% below its estimated fair value. The current Current Ratio is 6.06, which is 35% above median its 10-year median of 4.48 and 207.6% above the Drug Manufacturers industry median of 1.97. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ironwood Pharmaceuticals (FRA:I76), the current Current Ratio is 6.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ironwood Pharmaceuticals (FRA:I76) Overvalued in 2026?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued.
The current stock price of €3.66 is trading 3.9% below its estimated GF Value™ of €3.81.
GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:I76:
Current Ratio: 6.06 (35% above median its 10-year median of 4.48)
GF Value™: €3.81 vs. price of €3.66 (3.9% below fair value)
Industry Position: 207.6% above the Drug Manufacturers median (#107 of 995)
No single metric tells the full story. See the FRA:I76 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score
Get the complete analysis for FRA:I76
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I76 has been successfully added to your 
